Tuesday, July 3, 2012

Joy-rides Tablets





1. Name Of The Medicinal Product



Joy-rides Tablets


2. Qualitative And Quantitative Composition



Active constituent



Hyoscine hydrobromide 0.15 mg



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



A raspberry flavoured chewed tablet for oral administration.



4. Clinical Particulars



4.1 Therapeutic Indications



Anti-muscarinic. For the prevention of motion sickness.



4.2 Posology And Method Of Administration



Route of administration: Oral.








Adults over 13 years:




2 tablets 20 minutes before start of the journey. Maximum 4 tablets in 24 hours.




Children:




20 minutes before journey. 7 - 12 years: 1 -2 tablets. 4 - 7 years: 1 tablet. Maximum 2 tablets in 24 hours. 3 – 4 years: half a tablet. Maximum 1 tablet in 24 hours.



Not recommended under 3 years except on medical advice.



Ideally taken 20 minutes before the start of the journey. However, still effective if taken at onset of nausea or after the journey has begun.



4.3 Contraindications



Glaucoma.



4.4 Special Warnings And Precautions For Use



Do not exceed the stated dose. Avoid alcoholic drink.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



The actions of Hyoscine Hydrobromide may be potentiated by concurrent phenothiazines, tricyclic antidepressants or alcohol. Aluminium hydroxide preparations may reduce absorption of Hyoscine Hydrobromide. The actions may of tricyclic antidepressants may be potentiated by concurrent Hyoscine Hydrobromide.



4.6 Pregnancy And Lactation



Safety in pregnancy has not been established, but the drug has been used widely for many years without apparent ill effect. However, the normal precautions of avoiding unnecessary medication especially in the first trimester of pregnancy should be observed.



Hyoscine hydrobromide can cross the placenta and appears in trace quantities in breast milk.



4.7 Effects On Ability To Drive And Use Machines



May cause drowsiness, if affected do not drive or operate machinery.



4.8 Undesirable Effects



Some patients may experience dry mouth, dizziness, blurred vision and difficulty with micturition.



4.9 Overdose



The main symptoms are sleepiness, dry mouth, rapid heart rate, palpitation, dilated pupils. Take measures to limit intestinal absorption immediately. Parasympathetic agents such as physotigmine should be used as necessary. Do not use phenothiazines.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



The Atropine like actions of Hyoscine hydrobromide are well known. The site of action in preventing motion sickness is thought to be either on the cortex or more peripherally on the vestibular apparatus.



5.2 Pharmacokinetic Properties



Hyoscine is rapidly absorbed from the gastro-intestinal tract. About 1 % of an oral dose is eliminated as such in the urine. Traces are found in various secretions, including milk.



5.3 Preclinical Safety Data



None.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Mannitol



Erythrosine (E.127) Lake



Povidone



Raspberry Flavour Trusil J7551



Microcrystalline cellulose



Magnesium stearate



6.2 Incompatibilities



None known.



6.3 Shelf Life



3 years.



6.4 Special Precautions For Storage



Store below 25°C in a dry place.



6.5 Nature And Contents Of Container



Tablets are individually sealed in strips of 12, or as 2 strips of 6, between 2 layers of 0.25 mm soft aluminium foil/0.25 mm polyethylene. Strips are packed in decorated, folding boxboard cartons.



6.6 Special Precautions For Disposal And Other Handling



None.



Administrative Data


7. Marketing Authorisation Holder



Stafford-Miller Limited



980 Great West Road



Brentford, Middlesex



TW8 9GS



United Kingdom



8. Marketing Authorisation Number(S)



PL 0036/5004R



9. Date Of First Authorisation/Renewal Of The Authorisation



First granted 22 July 1973.



Last renewed 12 April 1996.



10. Date Of Revision Of The Text



17/09/2008




No comments:

Post a Comment